Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation
  • Cortexin®
    lyophilizate w / m 
    GEROPHARM, LLC     Russia
  • Cortexin®
    lyophilizate w / m 
    GEROPHARM, LLC     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    The mechanism of action of the drug is due to the activation of peptides of neurons and neurotrophic factors of the brain; optimization of the balance of metabolism of excitatory and inhibitory amino acids, dopamine, serotonin; GABAergic exposure; a decrease in the level of paroxysmal convulsive activity of the brain, the ability to improve its bioelectrical activity; prevention of the formation of free radicals (products of lipid peroxidation). The drug regulates the ratio of inhibitory and excitatory amino acids, dopamine and serotonin concentrations.

    The preparation contains a complex of low molecular weight water-soluble polypeptide fractions that penetrate through blood-brain barrier directly to nerve cells. The drug has nootropic, neuroprotective, antioxidant and tissue-specific effects.

    Nootropic action improves the higher functions of the brain, learning and memory processes, concentration of attention, stability under various stresses.

    Neuroprotective - protects neurons from damage by various endogenous neurotoxic factors (glutamate, calcium ions, free radicals), reduces the toxic effects of psychotropic substances.

    Antioxidant - inhibits lipid peroxidation in neurons, increases the survival of neurons in conditions of oxidative stress and hypoxia.

    Tissue-specific - activates the metabolism of neurons CNS and peripheral nervous system, reparative processes, contributes to the improvement of the functions of the cerebral cortex and the general tone of the nervous system.

    Pharmacokinetics:

    Not described.

    Indications:
    • Acute disorders of cerebral circulation
    • Craniocerebral injury and its consequences
    • Encephalopathy of various origins
    • Acute and chronic encephalitis and encephalomyelitis
    • Memory impairment
    • Asthenic syndrome
    • Encephalopathy
    • Viral and bacterialMr.Eroinfection
    • Decreased learning ability
    • Vegetative lability

    V.F00-F09.F06.6   Organic emotional labile [asthenic] disorder

    V.F80-F89.F80   Specific disorders of speech and language development

    V.F80-F89.F81   Specific developmental disorders of teaching skills

    VI.G00-G09.G04   Encephalitis, myelitis and encephalomyelitis

    VI.G40-G47.G40.9   Epilepsy, unspecified

    IX.I60-I69.I63   Cerebral infarction

    IX.I60-I69.I67.9   Cerebrovascular disease, unspecified

    IX.I60-I69.I69.3   Consequences of a cerebral infarction

    XVIII.R40-R46.R41.3   Other amnesia

    XVIII.R50-R69.R53   Malaise and fatigue

    XVIII.R50-R69.R62.0   Delayed stages of development

    XIX.S00-S09.S06   Intracranial injury

    Contraindications:

    Hypersensitivity, pregnancy, breast-feeding.

    Carefully:

    No data.

    Pregnancy and lactation:

    Category FDA not determined. The drug is contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intramuscularly 10 mg once a day. The course of treatment is 5-10 days, if necessary, the course can be repeated after 1-6 months.

    Side effects:

    Allergic reactions.

    Overdose:

    Not described, treatment is symptomatic.

    Interaction:

    Not described.

    Special instructions:

    Impact on the ability to drive vehicles and manage mechanisms not found.

    Instructions
    Up